LGS

Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Friday, March 8, 2024

In addition, Takeda is expected to read out results from two pivotal Phase 3 studies evaluating soticlestat.

Key Points: 
  • In addition, Takeda is expected to read out results from two pivotal Phase 3 studies evaluating soticlestat.
  • Of these potential future payments, Ovid sold a 13% interest to Ligand Pharmaceuticals for $30 million in October 2023.
  • Financial runway: Ovid anticipates its cash runway will support operations and clinical development programs into the first half of 2026.
  • Ovid also anticipates several events for its current pipeline programs and clinical results for soticlestat from Takeda in 2024.

Avicanna Obtains Its First Indication-Specific Drug Registration with Trunerox™

Retrieved on: 
Tuesday, February 13, 2024

“The approval of our first pharmaceutical product is an exceptionally significant milestone and a major step towards our long-term vision as a biopharmaceutical company with the aim to serve patients with unmet medical needs.

Key Points: 
  • “The approval of our first pharmaceutical product is an exceptionally significant milestone and a major step towards our long-term vision as a biopharmaceutical company with the aim to serve patients with unmet medical needs.
  • It is also rewarding to be able to deliver this medication for such a critical medical condition at an accessible price through our vertical,” stated Aras Azadian, CEO.
  • The approval allows Avicanna to manufacture and commercialize Trunerox in Colombia with approved indications and claims associated to the treatment for seizures related to Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (DS).
  • Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (DS) are two of the various, rare epileptic disorders classified as epileptic encephalopathies.

GN Fully Hydraulic Drive Centrifuge Improve Solids Control for Offshore Drilling Mud

Retrieved on: 
Saturday, February 10, 2024

HOUSTON and TANGSHAN, China, Feb. 9, 2024 /PRNewswire-PRWeb/ -- GN Solids Control, a pioneering force in separation technology, has unveiled its latest innovation: the GN Fully Hydraulic Drive Centrifuge. Engineered with precision for offshore drilling mud applications, this cutting-edge centrifuge marks a significant advancement in industrial separation, setting new standards in solids control for offshore drilling operations.

Key Points: 
  • GN Solids Control introduces the GN Fully Hydraulic Drive Centrifuge, revolutionizing offshore drilling mud solids control.
  • HOUSTON and TANGSHAN, China, Feb. 9, 2024 /PRNewswire-PRWeb/ -- GN Solids Control , a pioneering force in separation technology, has unveiled its latest innovation: the GN Fully Hydraulic Drive Centrifuge.
  • With a steadfast commitment to innovation, GN Solids Control is poised to shape the future of drilling mud solid control decanter centrifuge solutions in the offshore drilling industry.
  • For more information about the GN Fully Hydraulic Drive Centrifuge and other groundbreaking solutions, visit GN Solids Control's official website .

Longboard Pharmaceuticals Announces Positive Topline Data from the PACIFIC Study, a Phase 1b/2a Clinical Trial, for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (DEEs)

Retrieved on: 
Tuesday, January 2, 2024

Of the 52 participants enrolled in the study, 43 participants were randomized to bexicaserin (DS=4, LGS=24, DEE Other=15) and 9 to placebo (DS=0, LGS=5, DEE Other=4).

Key Points: 
  • Of the 52 participants enrolled in the study, 43 participants were randomized to bexicaserin (DS=4, LGS=24, DEE Other=15) and 9 to placebo (DS=0, LGS=5, DEE Other=4).
  • The median number of countable motor seizures per 28-day period at baseline was 38.8 in the bexicaserin group compared to 20.8 in the placebo group.
  • Most participants (85.7%) in the bexicaserin treated group (n=35) that started the maintenance period tolerated the highest dose (12 mg).
  • 100% of the participants who completed the PACIFIC Study elected to enroll in the ongoing 52-week open-label extension study.

AXSM FINAL DEADLINE NOTICE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important December 7 Deadline in Securities Class Action - AXSM

Retrieved on: 
Friday, November 24, 2023

WHAT TO DO NEXT: To join the Axsome class action, go to https://rosenlegal.com/submit-form/?case_id=2221 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Axsome class action, go to https://rosenlegal.com/submit-form/?case_id=2221 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

NeuroPace and the RNS System Showcased at the 77th American Epilepsy Society (AES) Annual Meeting

Retrieved on: 
Friday, December 1, 2023

“The Society’s annual meeting is the largest conference in the field of epilepsy in the U.S.,” said Martha Morrell, M.D., NeuroPace’s Chief Medical Officer.

Key Points: 
  • “The Society’s annual meeting is the largest conference in the field of epilepsy in the U.S.,” said Martha Morrell, M.D., NeuroPace’s Chief Medical Officer.
  • “We look forward to collaborating with the many healthcare providers, scientists, and others from all over the world who are gathering in Orlando to promote better outcomes for people with epilepsy.
  • We will host various presentations and events highlighting our RNS System and look forward to engaging with the broader scientific community in the epilepsy field.”
    Over 50 original scientific presentations and posters regarding the RNS System will be presented throughout the meeting, as well as a number of general meeting sessions that include how the RNS System provides an important therapy option for the treatment of drug resistant epilepsy.
  • These presentations, posters, and events involve key opinion leaders as well as early career scientists and clinicians, all of whom aim to improve the lives of patients living with drug-resistant epilepsy.

AXSM DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important December 7 Deadline in Securities Class Action – AXSM

Retrieved on: 
Tuesday, November 28, 2023

WHAT TO DO NEXT: To join the Axsome class action, go to https://rosenlegal.com/submit-form/?case_id=2221 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Axsome class action, go to https://rosenlegal.com/submit-form/?case_id=2221 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

AXSM FINAL DEADLINE ALERT: ROSEN, A LEADING LAW FIRM, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important December 7 Deadline in Securities Class Action – AXSM

Retrieved on: 
Friday, November 24, 2023

WHAT TO DO NEXT: To join the Axsome class action, go to https://rosenlegal.com/submit-form/?case_id=2221 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Axsome class action, go to https://rosenlegal.com/submit-form/?case_id=2221 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important December 7 Deadline in Securities Class Action – AXSM

Retrieved on: 
Saturday, November 18, 2023

WHAT TO DO NEXT: To join the Axsome class action, go to https://rosenlegal.com/submit-form/?case_id=2221 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Axsome class action, go to https://rosenlegal.com/submit-form/?case_id=2221 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

Madison Dearborn Partners Acquires T2S Solutions to Enable Continued Growth and Innovation in Support of U.S. Defense and Intelligence Missions

Retrieved on: 
Wednesday, November 29, 2023

The T2S founders will retain a significant minority ownership position and will continue to lead the Company.

Key Points: 
  • The T2S founders will retain a significant minority ownership position and will continue to lead the Company.
  • We’re excited to partner with MDP as we continue on our mission to deliver increasingly innovative technologies and solutions while maintaining our rapid growth.
  • Today, we are strategically positioned at the center of high-priority defense technology areas that will see significant growth for years to come,” said Tim Jahnigen, Co-Founder & Chief Growth Officer of T2S.
  • Raymond James served as financial advisor to MDP and Kirkland & Ellis and Crowell & Moring provided legal counsel.